Management of Older Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

The 2018 document discussed the treatment of older patients with metastatic renal cell carcinoma (mRCC) using Sunitinib, using a hypothetical case of a 75-year-old male patient. The patient experienced several side effects from the treatment, which were managed with various treatments and adjustments to the dosing schedule. The document emphasized the importance of individualized treatment plans and regular monitoring of the patient's response to therapy. It also highlighted that Sunitinib had comparable efficacy in older and younger patients with mRCC. The document concluded that older patients with comorbidities can be treated with Sunitinib using an approach of close monitoring, aggressive management of adverse events, and adjusting the treatment schedule as needed.